Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Long-Term Investments (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Long-Term Investments for 4 consecutive years, with $47.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments rose 696.66% year-over-year to $47.9 million, compared with a TTM value of $47.9 million through Dec 2025, up 696.66%, and an annual FY2025 reading of $47.9 million, up 696.66% over the prior year.
  • Long-Term Investments was $47.9 million for Q4 2025 at Zevra Therapeutics, up from $30.9 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $47.9 million in Q4 2025 and bottomed at $6.0 million in Q4 2024.
  • Average Long-Term Investments over 4 years is $18.3 million, with a median of $15.1 million recorded in 2025.
  • The sharpest move saw Long-Term Investments skyrocketed 33.94% in 2022, then surged 696.66% in 2025.
  • Year by year, Long-Term Investments stood at $14.9 million in 2021, then surged by 33.94% to $20.0 million in 2022, then crashed by 69.95% to $6.0 million in 2024, then soared by 696.66% to $47.9 million in 2025.
  • Business Quant data shows Long-Term Investments for ZVRA at $47.9 million in Q4 2025, $30.9 million in Q3 2025, and $15.1 million in Q2 2025.